Breakthrough in Bladder Cancer Treatment! Lin Tianxin and Chen Xu’s Team at Sun Yat-sen University First to Demonstrate Safety and Preliminary Efficacy of Intravesical Disitamab Vedotin in HER2-Positive High-Risk Non-Muscle-Invasive Bladder Cancer

Breakthrough in Bladder Cancer Treatment! Lin Tianxin and Chen Xu’s Team at Sun Yat-sen University First to Demonstrate Safety and Preliminary Efficacy of Intravesical Disitamab Vedotin in HER2-Positive High-Risk Non-Muscle-Invasive Bladder Cancer

2025.08.01
A research team led by Professor Lin Tianxin and Professor Chen Xu from the Sun Yat-sen Memorial Hospital of Sun Yat-sen University has published clinical trial results in the prestigious journal MedComm, titled “Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose–Escalation Phase I Trial Study.” This marks the world’s first clinical study to evaluate the intravesical administration of the HER2-targeted antibody–drug conjugate (ADC) disitamab vedotin (RC48) in patients with HER2-positive high-risk non-muscle-invasive bladder cancer (HR-NMIBC). The study offers a novel bladder-sparing strategy for patients who are unresponsive or intolerant to Bacillus Calmette-Guérin (BCG) therapy.
Exclusive Interview with EHA President | Professor Martin Dreyling: Unmissable Breakthroughs in Myeloma, Leukemia, and Lymphoma at EHA 2025

Exclusive Interview with EHA President | Professor Martin Dreyling: Unmissable Breakthroughs in Myeloma, Leukemia, and Lymphoma at EHA 2025

2025.07.31
The 2025 European Hematology Association (EHA) Annual Congress was successfully held from June 12 to 15 in Milan, Italy. Marking the 30th anniversary of the EHA, this year’s congress stood out as a major milestone, drawing over 15,000 experts and scholars from around the world with its global impact and groundbreaking research highlights. During the event, Oncology Frontier – Hematology Frontier had the privilege of speaking with Professor Martin Dreyling, Chair of the EHA 2025 Scientific Program Committee (SPC) and a professor at LMU Munich, to explore the most transformative scientific advances presented at the meeting.
EHA Highlight | Professor Evangelos Terpos: A Comprehensive Upgrade in MM Management—What’s New in the 2025 EHA-EMN Clinical Guidelines?

EHA Highlight | Professor Evangelos Terpos: A Comprehensive Upgrade in MM Management—What’s New in the 2025 EHA-EMN Clinical Guidelines?

2025.07.31
At the 2025 Annual Congress of the European Hematology Association (EHA), the much-anticipated updated EHA-EMN clinical practice guidelines for multiple myeloma (MM) were officially released. Covering key areas such as diagnostic assessment, risk stratification, treatment pathways, and follow-up management, the new guidelines provide more forward-thinking and practical guidance for clinical implementation.
Professor Yu Zhang: Optimizing the Diagnostic and Treatment Pathway for AML – The Southern Hospital Experience | 9th CSCO Hematologic Oncology Congres

Professor Yu Zhang: Optimizing the Diagnostic and Treatment Pathway for AML – The Southern Hospital Experience | 9th CSCO Hematologic Oncology Congres

2025.07.30
From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress hosted by the Chinese Society of Clinical Oncology (CSCO) took place in Harbin. The conference brought together leading experts from China and abroad to discuss key topics in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics ranged from basic research and innovative drug development to precision medicine strategies and clinical translation. At the conference, Professor Yu Zhang from Southern Hospital of Southern Medical University delivered a compelling presentation titled “Optimizing the Diagnostic and Treatment Pathway for AML at Southern Hospital.” In an exclusive interview with Oncology Frontier – Hematology Frontier, Professor Zhang shared further insights into the hospital’s innovative approaches and practical experiences in managing acute myeloid leukemia (AML).
Professor Lu Yang Explores Latest Advances and Combination Strategies in AR-Targeted Therapy at the 2025 Pujiang Prostate Cancer Congress

Professor Lu Yang Explores Latest Advances and Combination Strategies in AR-Targeted Therapy at the 2025 Pujiang Prostate Cancer Congress

2025.07.23
On June 27, 2025, the Pujiang Prostate Cancer Academic Congress was held in Shanghai, in conjunction with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Meeting of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Meeting of the Chinese Prostate Cancer Consortium (CPCC). The event gathered leading experts from around the world to discuss cutting-edge developments in prostate cancer treatment. Professor Lu Yang, Department of Urology, West China Hospital of Sichuan University, delivered a keynote presentation on recent advances in targeting the androgen receptor (AR) pathway in prostate cancer, providing important insights for clinical decision-making. He offered a comprehensive overview of the latest innovations in monotherapy, emerging evidence from combination strategies, and the translational potential of new technologies such as PROTACs and epigenetic modulators—while also addressing current challenges and future directions.